|
RYR vs. no intervention/placebo
| | | | |
|
Zhibituo vs. no intervention
|
1 [22]
|
62
|
-0.16 (-0.71 to 0.39)
|
0.57
|
|
RYR supplement vs. placebo
|
1 [7]
|
83
|
-1.04 (-1.38 to -0.70)
|
< 0.00001
|
|
Xuezhikang vs. placebo
|
4 [8, 24–26]
|
323
|
-0.74 (-0.93 to -0.55)
|
< 0.00001
|
|
Zhibituo vs. placebo
|
1 [29]
|
205
|
-0.20 (-0.53 to 0.13)
|
0.24
|
|
RYR vs. statins
| | | | |
|
Xuezhikang vs. simvastatin
|
13 [6, 30–34, 36–38, 40–43]
|
1238
|
0.14 (-0.05 to 0.33)*
|
0.14
|
|
Xuezhikang vs. pravastatin
|
7 [44–50]
|
587
|
-0.09 (- 0.20 to 0.02)*
|
0.11
|
|
Xuezhikang vs. lovastatin
|
3 [51–53]
|
191
|
0.00 (- 0.26 to 0.27)
|
0.98
|
|
Xuezhikang vs. atorvastatin
|
1 [54]
|
60
|
0.20 (-0.10 to 0.50)
|
0.19
|
|
Xuezhikang vs. fluvastatin
|
1 [55]
|
118
|
0.14 (-0.10 to 0.38)
|
0.26
|
|
Zhibituo vs. simvastatin
|
8 [32, 56–62]
|
601
|
0.22 (0.04 to 0.39)
|
0.02
|
|
Zhibituo vs. provastatin
|
1 [22]
|
62
|
-0.11 (-0.60 to 0.38)
|
0.66
|
|
Zhibituo vs. lovastatin
|
1 [57]
|
45
|
0.03 (-0.30 to 0.36)
|
0.86
|
|
RYR vs. non-statin drugs
| | | | |
|
Xuezhikang vs. inositol nicotinate
|
4 [66–68, 70]
|
299
|
-0.63 (-0.96 to -0.30)
|
0.0002
|
|
Xuezhikang vs. fenofibrate
|
3 [32, 74, 76]
|
220
|
-0.10 (-1.05 to 0.85)*
|
0.84
|
|
Xuezhikang vs. gemfibrozil
|
3 [77–79]
|
152
|
-0.34 (-0.58 to -0.10)
|
0.005
|
|
Xuezhikang vs. fish oils
|
1 [81]
|
95
|
-0.89 (-1.41 to -0.37)
|
0.0008
|
|
Xuezhikang vs. conjugated estrogens
|
1 [85]
|
44
|
-0.10 (-0.43 to 0.23)
|
0.55
|
|
Xuezhikang vs. biphenalbid
|
1 [87]
|
64
|
-0.06 (-0.32 to 0.20)
|
0.65
|
|
Zhibituo vs. fish oils
|
5 [97–101]
|
489
|
-0.57 (-0.70 to -0.45)
|
< 0.00001
|
|
Zhibituo vs. fenofibrate
|
1 [32]
|
90
|
0.3 1 (0.04 to 0.58)
|
0.02
|
|
RYR vs. RYR
| | | | |
|
Xuezhikang vs. Zhibituo
|
5 [32, 106, 108, 109, 111]
|
628
|
-0.08 (-0.18 to 0.02)
|
0.12
|
